Navigation Links
Major State Grant Accelerates Research and Development of Novel Cancer Therapy
Date:9/5/2008

BOCA RATON, Fla., Sept. 5 /PRNewswire-USNewswire/ -- The Florida Technology, Research and Scholarship Board recently awarded Florida Atlantic University researcher Dr. Herbert Weissbach, distinguished professor and director of the Center for Molecular Biology and Biotechnology in the Charles E. Schmidt College of Science, and CHS Resources LLC (CHS), $184,294 as part of the State University Research Commercialization Assistance Grant program (SURECAG). SURECAG was established by the Florida Legislature in 2007 to promote the commercialization of university research products to enhance the state's economy and its public universities. With these funds, universities are able to promote their commercialization endeavors by securing patents, establishing startup companies, developing licensing agreements and attracting private investments.

FAU, together with CHS (which licensed this technology from FAU), submitted a proposal for Weissbach's discovery of a novel combination of agents that work to preferentially target and kill cancer cells. In addition, CHS was instrumental in providing FAU with a matching grant -- a stipulation of the SURECAG program -- for a total of $368,588 for research and development. CHS is currently developing this therapy for treatment of actinic keratosis (AK), a precancerous skin condition, and "proof-of-concept" studies are ongoing. CHS is simultaneously developing an over-the-counter skin protective agent with unique antioxidant properties.

"SURECAG is designed to create a more vital link between venture capitalists, industry and Florida's state universities," said Dr. Gary Perry, dean of the Charles E. Schmidt College of Science. "This grant is essential to support product development activities necessary to help CHS obtain approval from the FDA to perform clinical trials that will lead to drug approval."

Weissbach and his team initially identified a lead compound that in combination with an oxidizing agent or age
'/>"/>

SOURCE Florida Atlantic University
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
5. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
6. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
7. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
10. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
11. Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... OAKS, Calif. , Sept. 1, 2015 /PRNewswire/ ... neuroscience collaboration with Novartis in the areas of ... potential entry into Alzheimer,s disease by teaming up ... Alzheimer,s disease program directed at genetically predisposed individuals ... enables Amgen to focus on the commercialization of ...
(Date:9/1/2015)... Israel , Sept. 1, 2015   ... leading innovator of less invasive, miniaturized circulatory support technologies ... announced today that it has entered into a definitive ... Valtech is a privately held company that specializes in ... and replacement devices for the treatment of the most ...
(Date:9/1/2015)... SALT LAKE CITY , Sept. 1, 2015 ... announced that it will present at the First ... Hotel in New York City.  Kelvyn H. ... to present to leading institutional investment representatives on ... The Ladenburg Thalmann Conference will showcase ...
Breaking Medicine Technology:Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... clinical research data suggests that [18F] Flutemetamol could add ... provide accurate identification of beta amyloid plaques, considered to ... (AD).  Flutemetamol, a GE Healthcare Positron Emission Tomography (PET) ... studied to identify the uptake of beta amyloid via ...
... 13, 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... received approval from the U.S. Food and Drug Administration ... ) Injection, the Company,s product used to treat acetaminophen ... Ethylene diamine tetracetic acid or any other stabilization and ...
Cached Medicine Technology:GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 2GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 3Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 2Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 3Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote 4
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Michael ... truth about medicine and health, truths that other doctors and professionals may be ... to regularly debunk certain misconceptions surrounding cholesterol, metabolically directed wellness, anti-aging, and more. ...
(Date:9/1/2015)... ... 01, 2015 , ... An August 25 article ... conducted each year on teenagers, quoting a New York City-area plastic surgeon who ... surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to patients and colleagues ...
(Date:9/1/2015)... Eagan (PRWEB) , ... September 01, 2015 , ... For many men, the first thing ... Men were often forced to wear a looser fitting shirt with a collar that ... neck, sliding a finger between their collar and skin all day because it’s uncomfortable. ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate Cancer Awareness ... more than 233,000 men each year in the United States. , Prostate cancer is ... cancer in America, affecting 1 in 7 men. One new case occurs every 2.3 ...
(Date:9/1/2015)... ... September 01, 2015 , ... In ... how many dental practices across the country are switching from traditional dental impressions ... Beverly Hills cosmetic dentist Dr. Sam Saleh of Ora Dentistry Spa, his practice ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Article on CAD/CAM Dental Technology Highlights the Advantages of 21st Century Dentistry, Notes Ora Dentistry Spa 2
... Compounded Hormones, WASHINGTON, Feb. 12 ... called on the American,Association of Clinical Endocrinologists ... to fully disclose their financial ties to ... that directly benefits,the pharmaceutical giant. In recent ...
... 12 TeamStaff, Inc.,(Nasdaq: TSTF ) ... services, announced today that it is changing ... Staffing Services, Inc., to TeamStaff,Government Solutions (dba ... subsidiary currently provides medical, office,administration and logistics ...
... families may have underlying speech deficits , , TUESDAY, ... or family history of learning disabilities may be more ... causes them to lose language abilities as they age, ... known as primary progressive aphasia, causes language abilities to ...
... YUCAIPA, Calif., Feb. 12 Ingen Technologies,Inc. (OTC ... the signed distribution agreement with Progressive International,Holding Co. ... Taiwan, People,s,Republic of China, Japan and Korea. Please ... Progressive International Holding Company (PIHK),( http://www.pgiholding.com ) and ...
... announcement by,the United States Food and Drug Administration that ... toxin type A), customers are,looking for alternatives to treat ... in 2002 for the temporary treatment of,moderate to severe ... 65 years,of age. In its recent communication, the FDA ...
... Feb. 12 Iomai Corporation,(Nasdaq: IOMI ) today ... the second dose of the two-dose regimen for its ... when,self-applied by subjects outside of a clinical setting., ... program for the,vaccine, measured the immune response to the ...
Cached Medicine News:Health News:American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Learning Disabilities May Presage Later Language Problems 2Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 2Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 3Health News:Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles 2Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 2Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 3Health News:Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: